



**meetings  
in a box**

ROAD TO



**ASCO GU 2025**

A cura di **Davide Soldato**, Genova

## PROSTATE CANCER – ADVANCED DISEASE

**TALAPRO-2** Talazoparib + enzalutamide vs enzalutamide in 1L treatment of mCRPC (LBA18)

**ENZA-p** Lu-PSMA-617 + enzalutamide vs enzalutamide for treatment of mCRPC (Abs 17)

**PSMAfore** Correlative ctDNA analysis from a study of Lu-PSMA-617 vs ARPI (Abs 16)

**WOLVERINE** Meta-analysis on locoregional treatment in oligometastatic prostate cancer (Abs 15)

**GROUQ-PCS 9** Locoregional treatment for oligometastatic mCRPC (Abs 22)

## UROTHELIAL CANCER – EARLY-STAGE DISEASE

**CheckMate 274** Adjuvant nivolumab vs placebo for MIBC (Abs 638)

**NIAGARA** Neoadjuvant durvalumab + chemotherapy vs chemotherapy for MIBC (Abs 659)

Durvalumab + chemotherapy for high-risk UTUC (Abs 661)

**RC48-C017** Neoadjuvant disitamab vedotin plus toripalimab for MIBC (Abs 665)

**RETAIN-2** Tailored treatment strategies for MIBC based on treatment response and genomic (Abs 815)

## UROTHELIAL CANCER – ADVANCED DISEASE

**EV-302** Enfortumab vedotin in combination with pembrolizumab vs chemotherapy in 1L la/mUC (Abs 664)

**TROPIONPanTumor01** Datopotamab deruxtecan in la/mUC (Abs 663)

**FORAGER-1** Novel FGFR3i in advanced solid tumors (Abs 662)

## RENAL CELL CARCINOMA – ADVANCED DISEASE

**CheckMate 9ER** Nivolumab plus cabozantinib vs sunitinib in 1L mRCC (Abs 439)

**COSMIC-313** Cabozantinib vs placebo in combination with nivolumab plus ipilimumab in 1L mRCC (Abs 438)

**KEYMAKER-U03 Substudy 03B** Pembrolizumab + novel agents based on molecular characteristics (Abs 440)